Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verona Pharma plc

72.73
+0.47000.65%
Post-market: 72.730.00000.00%19:54 EDT
Volume:1.45M
Turnover:105.46M
Market Cap:6.19B
PE:-36.05
High:73.93
Open:72.74
Low:71.19
Close:72.26
Loading ...
OverviewCompanyNewsFilings

Company Profile

Company Name:
Verona Pharma plc
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
209
Office Location:
3 More London Riverside,London,Greater London,United Kingdom
Website:
http://www.veronapharma.com
Zip Code:
SE1 2RE
Phone:
44 20 3283 4200
Fax:
- -
Introduction:
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Directors

Name
Position
David Ebsworth
Non-Executive Chairman of the Board
David Zaccardelli
President, Chief Executive Officer and Executive Director
Anders Ullman
Non-Executive Director
Andrew Sinclair
Non-Executive Director
Ken Cunningham
Non-Executive Director
Lisa Deschamps
Non-Executive Director
Mahendra G. Shah
Non-Executive Director
Martin Edwards
Non-Executive Director
Rishi Gupta
Non-Executive Director
Vikas Sinha
Non-Executive Director

Shareholders

Name
Position
David Zaccardelli
President, Chief Executive Officer and Executive Director
Mark W. Hahn
Chief Financial Officer
Claire Poll
General Counsel
Kathleen Rickard
Chief Medical Officer